Structure via PubChem · Public domain (PubChem)
fendiline
Sign in to saveFendiline is a nonselective calcium channel blocker and coronary vasodilator, originally developed for its anti-anginal and antiarrhythmic properties in the management of coronary heart disease.
Chemical data
- Formula
- C23H25N
- Molecular weight
- 315.5 g/mol
- IUPAC name
- 3,3-diphenyl-N-(1-phenylethyl)propan-1-amine
via PubChem
Drug data · ChEMBL
- Max clinical phase
- Phase 2
- Molecule type
- Small molecule
- Indications
- cardiovascular disease
via ChEMBL · EBI
Research
212 papers- Fendiline: a review of its basic pharmacological and clinical properties.Pharmatherapeutica · 1987
- Evaluation of fendiline treatment in VP40 system with nucleation-elongation process: a computational model of Ebola virus matrix protein assembly.Microbiology spectrum · 2024
- Fendiline-evoked [Ca2+]i rises and non-Ca2+-triggered cell death in human oral cancer cells.Human & experimental toxicology · 2009
- Fendiline Enhances the Cytotoxic Effects of Therapeutic Agents on PDAC Cells by Inhibiting Tumor-Promoting Signaling Events: A Potential Strategy to Combat PDAC.International journal of molecular sciences · 2019
- Basic mechanisms underlying prenylamine-induced 'torsade de pointes': differences between prenylamine and fendiline due to basic actions of the isomers.Current medical research and opinion · 1988
via PubMed
Wikidata facts
- Mass
- 315.199
Show 2 more facts
- chemical formula
- C₂₃H₂₅N
- canonical SMILES
- CC(C1=CC=CC=C1)NCCC(C2=CC=CC=C2)C3=CC=CC=C3
Sources (2)
via Wikidata · CC0
~1 min read
Article
2 sectionsContents
- References
- Further reading
Fendiline is a nonselective calcium channel blocker and coronary vasodilator, originally developed for its anti-anginal and antiarrhythmic properties in the management of coronary heart disease.
By inhibiting the influx of calcium ions into cardiac and vascular smooth muscle cells, fendiline promotes vasodilation, particularly of the coronary arteries, thereby increasing blood flow to the heart muscle, alleviating ischemia, and reducing chest pain associated with angina. Although its clinical use has become limited due to the availability of alternative treatments and its relatively slow onset of action, fendiline remains notable for its long half-life, lack of tolerance development, and demonstrated efficacy in improving exercise tolerance and reducing the frequency of angina attacks in placebo-controlled trials.